Showing results (131-140 of 166) with videos related to

Sort By:
Pageof 17
Journal of Thoracic Disease|September 18, 2020
The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapyTao Zhang, Nan Bi, Zongmei Zhou, et al.
Journal of the American Chemical Society|June 29, 2019
Stable and Active Oxidation Catalysis by Cooperative Lattice Oxygen Redox on SmMn2O5 Mullite SurfaceYongping Zheng, Sampreetha Thampy, Nickolas Ashburn, et al.
Thoracic Cancer|January 27, 2021
Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancerKunpeng Xu, Jun Liang, Tao Zhang, et al.
The Annals of Thoracic Surgery|August 11, 2019
Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung CancerJianyang Wang, Zhouguang Hui, Yu Men, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2016
A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung CancerXiao Ding, Zhouguang Hui, Honghai Dai, et al.
Journal of Medicinal Chemistry|May 23, 2025
Discovery of Orally Potent Small-Molecule CD73 Inhibitor for Cancer ImmunotherapyLifang Cen, Weijie Ren, Jiajie Yu, et al.
Cancer Letters|December 15, 2023
Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancerYufan Yang, Jianyang Wang, Jingbo Wang, et al.
Translational Lung Cancer Research|February 17, 2025
Clinical features and outcomes of unresectable locally advanced lung adenocarcinoma with uncommon EGFR mutations: a retrospective multi-center Chinese studyKunpeng Xu, Xiao-Li Zheng, Ming Chen, et al.
Thoracic Cancer|December 20, 2021
Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapyYufan Yang, Tao Zhang, Zongmei Zhou, et al.
Clinical Medicine Insights. Oncology|March 7, 2022
Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung CancerXiaotong Lu, Jingbo Wang, Chunyu Wang, et al.
Pageof 17